Dr. Zsebo is a biopharmaceutical veteran with 40 years of experience in the Biotechnology industry and has been involved in numerous successful ventures. She is CEO and co-founder of VST BIO. Prior to VST BIO, she was CEO & President of Celladon Corporation, for 11 years and took the company public. She was also an Entrepreneur in Residence at Enterprise Partners Venture Capital. Dr. Zsebo also headed the Biopharmaceutical and Implant Division of ALZA Corporation, where she was responsible for the division which developed and filed the NDA for Viadur®, an implantable drug/device for prostate cancer patients. At Cell Genesys, where she was Executive Vice President of Research, she managed the XenoMouse was creation, the first fully human monoclonal antibody producing mouse. Earlier in her career, Kris spent eight years at Amgen in research and product development where she worked on the discovery of NEUPOGEN®, as well as Stem Cell Factor, and various aspects of EPOGEN® development. Dr. Zsebo received a B.S. in Biochemistry from the University of Maryland, a M.S. in Biochemistry and Biophysics from Oregon State University and a PhD in Comparative Biochemistry and Molecular Biology from the University of California, Berkeley.